Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Dec 18;20(1):28–55. doi: 10.1038/s44320-023-00004-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Creative Commons Public Domain Dedication waiver http://creativecommons.org/publicdomain/zero/1.0/ applies to the data associated with this article, unless otherwise stated in a credit line to the data, but does not extend to the graphical or creative elements of illustrations, charts, or figures. This waiver removes legal barriers to the re-use and mining of research data. According to standard scholarly practice, it is recommended to provide appropriate citation and attribution whenever technically possible.

PMC Copyright notice

(A) Result of elastic net regression for the MAP2K inhibitor Cobimetinib highlighting proteins and phosphorylation sites indicative of drug resistance or sensitivity. (B) Same as panel (A) but for the FGFR inhibitor Infigratinib. (C) Correlation analysis between the level of phenotypic response of cell lines towards Infigratinib and the abundance of ERBB2 S1054 (top panel) and the abundance of TOP2B S1552 (bottom panel). (D) Time-dependent analysis of FRS2 S428 (top panel) and GAB1 T503 (bottom panel) in response to Infigratinib in G401 cells. Both phosphorylation sites are known members of FGFR signalling. (E) Same as panel (D) but for two novel phosphorylation sites ERBB2/HER2 S1054 (top panel) and TOP2B S1552 (bottom panel). Source data are available online for this figure.